China Conducts First Centralized Purchasing For Medical Consumables
This article was originally published in PharmAsia News
China's Ministry of Health has successfully conducted the 2008 national centralized purchasing of high-value medical consumables, at an average 10 percent lower rate. The first such exercise to supply medical institutions nationwide, the products purchased are classified into four categories: cardiac pacemaker, electrophysiology, cardiac intervention and peripheral vascular intervention (neurological intervention). MOH will publicize candidates' product catalogs and pricing in the near future. Non-profit medical institutions across the country may purchase these items; in principle, they should not buy similar products outside the catalog. Experts point out that the centralized purchasing can unify pricing of different regions in China, paving the way toward formulating standardized charging for medical care services. (Click here for more - Chinese Language)
You may also be interested in...
China's Ministry of Health has published the 2008 candidates' product catalogs for the national centralized purchasing of high-value medical consumables (PharmAsia News, Aug. 11, 2008), with the details posted on its International Communication and Cooperation Center website. MOH requires all regions to execute the purchase from Oct.1, within a one-year purchasing cycle. China's urban health care institutions' expenditure on medical consumables increased at an annual rate of 22.4 percent from RMB 9.693 billion ($1.417 billion) to RMB 39.831 billion ($5.825 billion) between 2000 and 2007, far exceeding drug expenses. Experts reveal that the government plans to include all medical devices into centralized purchasing by 2010. The country's increased investment of RMB 150 billion in public health and government purchase, with priority for local brands, will boost the domestic medical devices industry. (Click here for more - Chinese Language)
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.